Extensive peptide certification includes the science of LL-37 . Elsewhere, we have mentioned it has antibacterial, antivirus, antifungal, and biofilm destructive effects… What about Babesia and the huge numbers of people in over 50 nations with malaria?
LL-37, a human antimicrobial cathelicidin peptide, exhibits antimalarial activity by inhibiting the asexual blood stage of Plasmodium parasites.
LL-37 reduces parasite levels, particularly in mouse models (e.g., P. yoelii), by targeting the parasite’s membrane integrity. It also plays a role in enhancing innate immunity to control infection
Key Findings on LL-37 and Malaria:
- Antimalarial Action: LL-37 directly kills malaria parasites during the blood stage, reducing parasitemia. [all Babesia medications are malaria medications. And Babesia is much harder to kill based on 27 years of self-funded research].
- Mechanism: As a cationic host defense peptide, it acts by disrupting the parasite membrane, a mechanism similar to its antibacterial activity.
- Therapeutic Potential: Due to its ability to modulate the immune system, LL-37 is considered a candidate for increasing your defense against infections, including malaria.
Research suggests that enhancing the body’s natural production of peptides like LL-37 could potentially aid in controlling parasitic infections.
Cancer and LL-37
Some argue that: LL-37 induces tumorigenic effects in cancers of the ovary, lung, breast, prostate, pancreas, as well as in malignant melanoma and skin squamous cell carcinoma. 1
In contrast, LL-37 displays an anti-cancer effect in colon cancer, gastric cancer, hematologic malignancy and oral squamous cell carcinoma. 1
1. Chen X, Zou X, Qi G, Tang Y, Guo Y, Si J, Liang L. Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. Cell Physiol Biochem. 2018;47(3):1060-1073. doi: 10.1159/000490183. Epub 2018 May 25. PMID: 29843147.